<DOC>
	<DOCNO>NCT00841087</DOCNO>
	<brief_summary>This trial conduct Japan . The aim clinical trial investigate safety ( emphasis hypoglycaemia ) switch long-acting insulin analogue intermediate-acting insulin insulin degludec ( NN1250 , SIBA ) basal-bolus regimen subject type 1 diabetes mellitus .</brief_summary>
	<brief_title>Comparison NN1250 Versus Insulin Detemir , Both Combined With Insulin Aspart Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Subjects type 1 diabetes mellitus one year Current treatment : basal ( daily bedtime ) bolus ( three time day main meal ) regimen least 12 week use longacting insulin analogue exclude insulin detemir intermediateacting insulin basal insulin NovoRapidÂ® bolus insulin ( brand basal insulin preparation change precede 12 week ) HbA1c 10.0 % Body Mass Index ( BMI ) 30.0 kg/m^2 Known hypoglycaemia unawareness recurrent major hypoglycaemia Current treatment total insulin dose 100 U IU/day Current treatment expect start treatment systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>